-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 TpiP0TyBm2SpMLUlhhcEJNyF1Ym3dqjNAYMe7J2ngeE+A8Pe+cfOqvvF1Fw5x+i6
 MSqMyJJUW+/EP/tCRent2Q==

<SEC-DOCUMENT>0000950123-09-070913.txt : 20091215
<SEC-HEADER>0000950123-09-070913.hdr.sgml : 20091215
<ACCEPTANCE-DATETIME>20091215164442
ACCESSION NUMBER:		0000950123-09-070913
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20091209
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20091215
DATE AS OF CHANGE:		20091215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		091242157

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c93722e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): December 9, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>CYCLACEL PHARMACEUTICALS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>0-50626</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>91-1707622</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>200 Connell Drive, Suite 1500<BR>Berkeley Heights, New Jersey<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>07922</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(908) 517-7330</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>Item&nbsp;3.01</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer or Listing.</B></TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt; text-indent: 4%">On December&nbsp;9, 2009, Cyclacel Pharmaceuticals, Inc. (the &#147;<U><B>Company</B></U>&#148;) received a determination letter from
the NASDAQ Listing Qualifications Staff (the &#147;<U><B>Staff</B></U>&#148;) at The NASDAQ Stock Market LLC (&#147;<U><B>NASDAQ</B></U>&#148;)
notifying the Company that it does not comply with the $10&nbsp;million minimum stockholders&#146; equity requirement of the
continued listing rules of The NASDAQ Global Market (&#147;<U><B>Listing Rules</B></U>&#148;) set forth in NASDAQ Marketplace Rule
5450(b)(1)(A), and that the Company&#146;s securities are subject to delisting, unless the Company appeals the Staff&#146;s
determination to the NASDAQ Listing Qualifications Panel (the &#147;<U><B>Panel</B></U>&#148;) by no later than December&nbsp;16, 2009.


<P align="left" style="font-size: 10pt; text-indent: 4%">The Company intends to request a hearing before the Panel by no later than December&nbsp;16, 2009, consistent with
instructions contained in the determination letter, which will stay the Staff&#146;s determination to delist the Company&#146;s
securities on The NASDAQ Global Market pending the issuance of the Panel&#146;s decision. Under NASDAQ&#146;s Listing Rules, the
Panel may, at its discretion, determine to continue the listing of the Company&#146;s securities on The NASDAQ Global Market
for a maximum of 180&nbsp;days from the date of the NASDAQ&#146;s determination letter, or through June&nbsp;7, 2010. There can,
however, be no assurance that the Panel will grant the Company&#146;s request for continued listing.


<P align="left" style="font-size: 10pt; text-indent: 4%">On December&nbsp;15, 2009, the Company issued a press release announcing its receipt of NASDAQ&#146;s determination letter.
A copy of the press release is being furnished as Exhibit&nbsp;99.1 to this report and is incorporated herein by reference.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>Item&nbsp;9.01</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Financial Statements and Exhibits.</B></TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt; text-indent: 3%">(d)&nbsp;Exhibits:


<P align="left" style="font-size: 10pt; text-indent: 3%">The following exhibit is furnished herewith:


<P align="left" style="font-size: 10pt; text-indent: 3%">99.1 Press release, dated December&nbsp;15, 2009

<P align="center" style="font-size: 10pt; text-indent: 3%">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.



<P align="left" style="margin-left:46%; font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B>



<P align="left" style="margin-left:46%; font-size: 10pt">By: <U>/s/ Paul McBarron&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Name: Paul McBarron<BR>
Title: Executive Vice President &#151; Finance,<BR>
Chief Financial Officer and Chief<BR> Operating Officer&nbsp;<BR>


<P align="left" style="font-size: 10pt">Date: December&nbsp;15, 2009


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c93722exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">


<P align="right" style="font-size: 10pt"><B>Exhibit&nbsp;99.1</B>


 <P><DIV style="position: relative; float: left; width: 48%">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><IMG src="c93722p9372201.jpg" alt="(LOGO)">

</DIV>
</DIV>
<DIV style="position: relative; float: right; width: 48%">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt">&nbsp;
</DIV>



<DIV align="right" style="font-size: 10pt; margin-top: 10pt">Cyclacel Pharmaceuticals, Inc.
</DIV>

</DIV>
<BR clear="all"><BR>


<P align="center" style="font-size: 10pt"><IMG src="c93722p9372202.jpg" alt="(PRESS RELEASE)">

<P align="center" style="font-size: 10pt"><B>CYCLACEL RECEIVES NASDAQ NOTICE OF NON-COMPLIANCE</B>



<P align="justify" style="font-size: 10pt"><B>Berkeley Heights, NJ, December&nbsp;15, 2009 </B>&#150; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &#147;Cyclacel&#148; or
the &#147;Company&#148;) today announced that, on December&nbsp;9, 2009, the Company was notified by the NASDAQ Staff that the Company
does not comply with the minimum $10&nbsp;million stockholders&#146; equity requirement set forth in NASDAQ Listing
Rule&nbsp;5450(b)(1)(A) (the &#147;Rule&#148;) and that the Company&#146;s securities are subject to delisting from The Nasdaq Global
Market unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel (the &#147;Panel&#148;). Cyclacel
intends to timely request a hearing before a Panel, which automatically stays the delisting of the Company&#146;s securities
pending the issuance of the Panel&#146;s decision after a hearing.&nbsp; Under NASDAQ&#146;s Listing Rules, the Panel may, at its
discretion, determine to continue the Company&#146;s listing pursuant to an exception to the Rule for a maximum of 180&nbsp;days
from the date of the Staff&#146;s notification or through June&nbsp;7, 2010. However, there can be no assurances that the Panel
will do so.


<P align="justify" style="font-size: 10pt"><B>About Cyclacel Pharmaceuticals, Inc.</B>


<P align="justify" style="font-size: 10pt">Cyclacel is a diversified biopharmaceutical company dedicated to the discovery, development and commercialization of
novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Sapacitabine, a cell cycle
modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly,
myelodysplastic syndromes and lung cancer and in Phase 1 in combination with seliciclib. Seliciclib, a CDK (cyclin
dependent kinase) inhibitor, is in Phase 2 for the treatment of lung and nasopharyngeal cancer. CYC116, an Aurora
kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Cyclacel&#146;s ALIGN Pharmaceuticals subsidiary
markets directly in the U.S. Xclair&#174; Cream for radiation dermatitis, Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges for
xerostomia. Cyclacel&#146;s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology
based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit
<U>www.cyclacel.com</U> for additional information.


<P align="justify" style="font-size: 10pt"><B>Risk factors</B>


<P align="justify" style="font-size: 10pt">This news release contains certain forward-looking statements that involve risks and uncertainties that could cause
actual results to be materially different from historical results or from any future results expressed or implied by
such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the
efficacy, safety, and intended utilization of Cyclacel&#146;s product candidates, the conduct and results of future clinical
trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering
activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or
later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated
with reliance on outside financing to meet capital requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and commercialization of product candidates. You are
urged to consider statements that include the words &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;believes,&#148; &#147;estimates,&#148;
&#147;projects,&#148; &#147;potential,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;intends,&#148; &#147;continues,&#148; &#147;forecast,&#148; &#147;designed,&#148; &#147;goal,&#148; or
the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are
more fully discussed under &#147;Risk Factors&#148; in the Annual Report on Form 10-K for the year ended December&nbsp;31, 2008, as
supplemented by&nbsp;the interim quarterly reports, filed with the SEC.


<P align="justify" style="font-size: 10pt"><B>Contacts for Cyclacel Pharmaceuticals, Inc.</B>


<P align="justify" style="font-size: 10pt">Investors/Media:
<BR>
Corey Sohmer, (908)&nbsp;517-7330
<BR>
<U>csohmer@cyclacel.com</U>


<P align="justify" style="font-size: 10pt">&#169; Copyright 2009 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&#174; are trademarks
of Cyclacel Pharmaceuticals, Inc. Numoisyn&#174; and Xclair&#174; are trademarks of Sinclair Pharma plc.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT style="font-family: Wingdings">&#254;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">200 Connell Drive, Suite&nbsp;1500, Berkeley Heights, NJ&nbsp; 07922 USA T: &#043;1 (908)&nbsp;517 7330 F: &#043;1 (866)&nbsp;271 3466</DIV></TD>
</TR>


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT style="font-family: Wingdings">&#168;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><DIV style="text-align: justify">Dundee Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel &#043;44 1382 206 062 Fax &#043;44 1382 206 067</DIV></TD>
</TR>
</TABLE>




<P align="center" style="font-size: 10pt"><U>www.cyclacel.com</U> &#150; <U>info@cyclacel.com</U>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c93722p9372201.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c93722p9372201.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%$`P@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`^9/BM^U7\-_AC<7.C6\DWB_Q1;$QSZ+H,L/V>PF
M'6+5=8?=;V<H/#0QBXF0\/$M??<.>'>>Y]"GB91CE>7SUC7Q"DI5(OK1H*TY
MI])2Y(2Z39^9<5^*O#?"]2I@Z<I9OFE+26'PLH\E*7\M?$.].F^CA%5*D7I*
M"/C?5/VT/C5XFN6M_!^AZ'HZ,QCA@TC1+_Q-J2EL%0\UP\D+S8#8`LE!!^Z<
M9K]0P_A7PIET%/,\77Q+6K=:O3PE+3>T8J,E'7_GZWYGXYBO&?C7,ZCIY/@,
M-@E+2,:&&JXRLF^\IN4'+1VM1BFNA@2_M(?M4Z,8[S5+W7(;8,&$>K?#?2K.
MRD#?,JM+%X9M9=I`.-DZDCOWKLCP+X=XA.EAZ.'=3O1S.M.:MN[/%5(W]8->
M1Y\O$?Q5P+C6Q5?$PI)IVKY1AZ=-IZI<T<'2E9]+33\ST#P=^W?XLM)HH?&_
MA/1M<L0=LU[X<DGT?4T!)W2?9+RXN;6Y91TC#VN=O+`G(\;,_!_+9QE+*,QK
MX.KO&GB5&M2?ESTXTZD4_P":U3?8^@R;QWS6C.,,[RG#XVA>SJ81RP]9)]>2
MI*I2FUTBG23[H^\_AI\8/`/Q8T]KWP=K*3W-NBOJ&BWB?8M<TS<=H^VZ<[%O
M*+$`3PM-`Q.%E)XK\=SWAC..&JRHYGA73IR=J=>#Y\/5Z_NZB25[:N$E&HMW
M%(_>>&N+\AXKP[K9/C%.I32=7#5%[/$T+NW[RDW?EOHJD'.FWHIMZ'I]>`?3
MA0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'Y]?M&?'SQ-KGB1O@A
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MO*:W+GF;5N(LUBWSJI6Q&*J<[LVO8X5N,/\`#5J2=KW;L>EA\Y\5,YH*7#>1
MT.$\E:7LW2P^%P5%4[-1?ML8HRG?7WZ-.*;LTE?7)M;;]L2VF,^C_$>T\0WL
M!)_LO3?B!X(URY?<VPXTN[D$<V'.-F"<\*I/%=-2?AC*"AB<CG@:4O\`E[5R
M['X>*TO_`!8+FCIK>Z75LY:=/Q@I3Y\%Q'3Q]>GK["CFN6XF;N[?P*DW&6NE
MK7OHET//M=^(,5SJ1\._M&?!^&#4G`#>*?#NB_\`"!^/K-6V@WZ1Q)'IOB2)
M4&1&\:Q-N.&/R@>U@\EE2H?7>!N)I2H1VP>)K_7\NF]?W;;;KX5M[R4G)=EJ
MW\]CN((5,2\N\1N#XT\0_P#F.PF'_LO-*:>CJI14<-C(K>,904'?XGH4[7X-
M_$71M6T'QQ\!-5O?'>C75V?^$?\`%?AG98:IH]VKH)M'\8:5<2H=(G0.BW"3
MAK66)]S;5?8-*G$^1XC#8S*.,<-#)\52A_M&#Q5YT:T&G:M@JL4U6C*S=-PM
M5A-65VN8RH\&\18+%X#/.`L74SS`U:G^RXW!6I5\/--<V'Q]";3P\XJ2515$
MZ%2#O*T9<I^D_P`._P!H[X-?$#QAJGPK\/?$[PAXA^*?A*R_XJ[PQHUX[RVM
M_8>7:ZZNGS/"MMJJ66HEX;A;":Y-JQ"7`C;BOY?K^Q]O6^KW]ASS]GS?%[/F
M?)S>?+:_F?V/AO;_`%?#_6>7ZS[.'M>3X?:\J]IR_P!WGO;RL>\5D;!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!X7^T7\37^%/PMUS7;&41:]J&S0?#
MAXW1ZKJ22@7H7.2+.SCNKOH06MD4_?KZ[@?(%Q#Q#A,'5C?!T+XC$^=&DU[G
M_<6;A3[VFVMCX;Q%XF?"G"V-QU"7)C\1;"X/O&O64OWB7_3FFIU=FG*$4_B/
ME#P;I=M^S%\&6^)>JV']I?&3XDK%8^&K*\1KN[LGU8?:;&R\G)E=UB8:AJ&W
MYYIW@M"00A/Z-FF(J<>\4K(<-6^K\+Y$W4Q,X-0A-4?<J5+_``I-_N</?W84
MU.LKIM'Y3DV%I>&/!CXEQ5#ZSQEQ&HT\'3J)SJ4W77/3I\OQW47]8Q5K2J57
M3H-IV;P+/PO)\*[O2M3U[1&^+?[4OQ&+ZSI7AS41_:.G^"X[OYO[9UJ%F"/?
M0[7'FR-%'$8)(X'@@M6FE[*N81X@I8C#X+%KAGP]R*U&MB:7[JIC7#3V%!K5
M4YW7NQ4I3YE*HJE2HJ<?/HY5+A6KA<5C\$^+/%'B&^(H82M^]I9<JFOUC$1N
MHNK"S]Z3C"')*-.5.E2E5GF^+_#.C7NN?8_CM\3_`![\4_B'('>;X9?".S_M
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M^`=8M8G\X;YGLGC0JQC#@CS,3B<HC5Q6+G"7`/%N!IRK24G".'QJBG+E:ARX
M;,*-1KETBJZD[I2:U];!X//?8X+`TYQ\2^",QJQP\91526*R^4VHJ2Y^;%Y5
MB*:?.KR>&<-).*E=-^)OQ.U;]AZ?X>:#\!_A;XC_`&@-.^+GCJ[T_P`5:S::
MC-J/]E76BRZ;I]GX/TL^&M.EM+3Q3/;:C>.CWX3)L9#)'(J-]D_'N*.*\?Q3
M7PE;&T:.'^ITG3A&C&25YM2G)N4I2?-)*T;\L5HE=MO]YX.X*RW@G#8W#9=B
M,1B?KM559SQ$HMI03C3A%0C"*Y5)WER\TV[R=E&,?1/@+_P3B^&7P%_:#US]
MH#0_&'BS5KV\?Q--X;\*:G%80V/AF7Q=]H35!<:E;9GUP0V=Y=VML)$M]B3;
MYC<3(LH^7/L=OD?HM0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`TLJE5+*K,2$4D
M`L0,D*#U.,GB@!U`!0`4`?%/[0NG+X^^.?P#^&,RB;3([C5/&6N6@WE9+"SD
M5U^T*%*^5)#HFH6ZL1_R]2`D;LU^J\%5O[%X1XQS^'N5W&E@L//1<M2::?+L
M[QE7IS:_N1>MC\5\0L.L^XXX"X8E[V&C.MF&)IJ]I4H._OJS7+*.&JTU_P!?
M)*ZN:GB&VM_&_P"U`DFL@-X4^`W@6'Q*ULP\R`^)=;WWEO<F(-CS(;**&X48
MR'TJ/LPKGP4YY1X?N.$]W,>,,?+"J2]V2PM"T)1O;:<W*#[QK2['7F%*GG7B
M:I8RSRK@3+8XQP>L?KF(_>QGRIVO&GR5(Z74\/'N>?>%XO$U_I$/C/39OL7Q
M=_:;UV_&E:[.GG2?#SX4::C7$UY8F0CR#:Z!%9M%AD\RXU'3\G=`"?:Q[P%#
M$SRNM#VG#7`.'I^UP\7RK,<WJOEC"=OB]IB)34[I\M.G6Z39X.61S*MA:>;X
M>7L.+O$K%551Q$ES/*LCHKGG4INZ4?986--TVI1YZE7#Z\U-7[WX;_#.\UO2
MGA\$:QJ?PR^%8N94LM8\/_9X_B;\5)X)&BNO&6N>*[RWFFTK2+RZ6:2SB@B$
MT\+"<F&"6*(>/GF?4L%B(RS7"TL]XAY4YT,1S/*\HC)7C@J&$A*$:M:E!Q5>
M4Y<D)WA:<XSF>YPYPU6QV%E#),96X9X6YY*GB,)R1SG.Y0ERSS#$8Z<92H8>
MM-2>'A"'/4I-5/W=.5."[>_^`6IZ7#+=_#_XM?$G0]:5-R0>)_$,_C;POJ<B
MQNK0:WH>N)*)K>X+%9&BD38'8HAP%KR:/&.'K2C2SCAO+,5A;ZRPN&C@,523
M:?-0KX=QY90WBI1?,TE*74]ROP%B<+"57(.*\XP6,C'2&,Q<LPP59I-..)PV
M(4E)5+M3DGHFVH.R1YIH^A:[X>\47>B?!CPM\/+7XF1>)_AC#^TS;:I;_$/0
MO`]OX#\2:?K.H:E>_"F<64&G:AXB>.-Y4AM'DCMI)#%=B-V13Y>?\18O-_8X
M)XROB<KRZ=7ZD\7&D\7&G.R2KU87=2:C%1NYR5E<]CACA7`Y#[?'QP.&P.<9
MI3I?V@L#*M'!.K3YG)X:A4:5&$I2E*RA'5OSOZM^SG^S+\,_V6_"VO\`@_X7
MKXA72?$?BB\\6ZBWB/66UF\_M*\M+.Q$,$_V>`1VD-G86T2!D>5@FZ::60EZ
M^:/K=O(^A*`/EOXI?MD?`3X2^*CX`UCQ+JOB7XAQQK+-X!^'/A?Q!X_\56B/
MY>P:C8>&;"ZCTF9O.A*PWT]M*PGC94*N"0#GY/VY_@)9^"+CX@ZI<>/=`\-Z
M3XRT;P+XIE\0_#?Q?H-YX+US7XI)=+D\56&J:9!+I^D3>4T9U&-;BV25DA>1
M9I%1@#ZHUOQ+H/AOPYJOB[6M5LM.\,Z)H]YX@U36IYT&GV>BV%G)?W>HO.A*
MFU2SC>7>N[*C*YR,@'D6B?M*_"'5/@U8_'W4O$C>"OA;J<4ESI_B#QY93^%'
MO+7[5-9VES:Z=J(6ZN$OY8':R2.)I;R,I);QR)*C.`>1:#^WW\`/$6JZ-9:=
M%\5ET;Q%J^GZ%H7C6\^#?Q&LO!.I:GJMS%:Z?!#KLWA]1"DTUQ;XFN(88D6=
M9)'2,,R@'T#X?^,O@7Q+\5?'WP8TF\OI/'7PTTKPWK/BJSETVY@L+6Q\5VBW
MNCM::DZB&]D>W=2Z1$E"<'D'`!ZK0!\YV/[5?P3U#X_7_P"S/:>)YG^*^FVD
MMS/I1TN]72WG@T:W\0W.F6^M^5]DGU6'1KE;F2V1RR+%,A/F1.@`/H*^OK+2
M[*[U+4KRUT[3M/MI[R^O[ZXAM+*QL[:-IKBZN[JX=(K:VBB1W>61E554LQ`!
M-`'Q3<_\%"OV;C=WT?AF^^(OQ`TG2998M8\5_#WX4>/O%?A#2C"YCFEG\0:?
MH?V:YME?`\^R-U$2PVNW.`#K_B/^VG\"?A?8_"S4-<U+Q9J4'QGT"X\3?#N'
MPQX&\3Z[J.MZ/;6FFWTL[:1;:>+ZQG%IJMI*;:YMHIE!DWQJ8G"@&]\*/VJ?
MAG\8[SQ'9>%M,^(^FR>%M!D\1ZI-XQ^''BKP?:'3HI1#(ME=:Y801WMX&.[[
M/$QD*AF`(5L`'>_!7XS^!/C]\/M*^)WPVO;Z_P#"6LW6J6=C<ZCIMSI-VT^C
MZA<:9?+)97:K)&%N[:502,,`&'!H`XWXF?"KQGXM\5PZQH7BZYT>P-@+-[:&
M7RE#?N/)%T2C2);6-W$=7MFLRLDMY^XN`+<^8`#Z(H`*`"@#Y0\0V;)^V/X!
MO94VPS?!S6;>RD)VA[NSUG7'NXU'=DMM1A8CTESVK]&P55?\0PSBC!^_'.J,
MIKM"='#J#\N:=*2^7F?E.84)+QBR'$2C:E+A^O"G+:]2&(Q;G%>:IU4_G<RO
M[*O#XF_;0MH"PU35/"WA^33L$+B&\^'&LPV/ER#E&-U'.",@#8I[UT?6*2P'
MA9.22P^'Q>)53_%#,Z$JEUM;D<7?K=G)]5K?VGXSTJ=UBL3@<(Z73W:F48F-
M*SW3<U)-=+)EQ[#S-*\*RZ9%&)(_V5?$5MH#(BK!'/-;>$!<?9I57$<QA^R`
M;#DJ2<8&:R5;DQ&81KR?*^+<-+$)OWG&,L;R\T;ZKFY]U9/U-GA^;"95+"Q2
M<>!\7#"M*T8RE#`<_(TK*7+[.UM6K]CZCT*WL;/1-'M-,6---M=*T^WTY(B#
M$MC!:0QVBQ$=8Q;K&%/H!7Y]BYUJF+Q53$-NO4JU)5&]_:2FW._GS-W\S]1P
M-.A1P6#I85*.&I4*4**C\*I1IQC34?)02MY%?7]%.O6<>FR7LEMIDTLT6MV*
M6]K-'KNC7>GWUC>:)<R3QM)9V\QNXI3/:/#.#:*JR!))`W.=19T/1-+\,Z+H
M_AW0[--/T70-+L-%TBPB>62.QTS2[6*QL+2-YG>1TAM8(HPTCNQ"`LQ.20-O
M*QJ4`<'\5/$=]X.^&'Q'\7:6(FU/PKX#\7^(].6=2T!OM#\/:CJ=H)E'WHC<
M6L>X=QF@#XZ_X)J^`O#N@?LO>#/B%`+?5O'?QADUOQ]\1?&DPCN-<\1Z_J?B
M+5@T.HZDVZ:1+".);;R#)L6X2[FV++<S%@#[,^(WP^\+?%3P+XK^'7C/3DU+
MPQXRT2\T+6;0[5E-K=1D1W%K*5;[/?6MQY=U;3J-T-Q!%*F&0&@-O(_&KPO8
M_&WXG:AI7_!,OQO_`&BNA?"/Q$-2^+GQ3@O/(D\:_LUZ!)I>J?#3P_8F.4S6
MVKZ\]]I6F7&&W6UOI<09IS'>I0'X'T#\9?#/A[X@_M]_LQ_`3Q'8:6?A-\+_
M`(,ZU\6=`\!2Q(OA_5?%-A?ZIX8T&VFT<*+:[@T:PT2SN+:W='C2*UNXRGE3
M2(X!^HX10H0*H0+L"``*%`P%"XP%QQB@#\Z?@K_RD:_;-_[)S\"?_4<@H`^W
M?BA\0-$^$_PY\;?$GQ')Y>B>!_#.L>);]0P62>/2[*6YCLK?/WKN[G2*VA0<
MO+<1J.6%`'XM:E\,_$?@;]D/P!^U^9;.Y_:#\/\`QE_X;`\9)!<VJZCJ?ASX
M@WT$'B+P>QDE::#2U\`3Z)++9E@L"V=]$L8,C"@/P/I?_@H-X[@^('P>_9G\
M(^&]6OHOAU^T[\;_`(2>&O$FM:5<-:27_P`/?$WEZM_9XN(V`B-Z)["Y*E\$
M::Z.&4N``?I=X<\-Z!X/T+2?"_A;1]/\/^'="L8--T?1M*M8K+3].L;5!'!;
M6MM"JK&BJ/3))+,2S$D`_++]N+Q1K?@;]LC]ACQ/X9\#Z[\1=9T>W^-LEAX(
M\+36=KKFMFX\-Z;:3Q6$M\RVZ?9[:>:[D\QE!BM90""0:`V\K'V#\/OC)\0/
MBGX>^)-OXU_9]^(7P2BT7PK<S:?=^-[[0KN+Q!)>V.JI<6^GKH]Q(T<EHMO$
M\AD`!%VF#D&@-O(\&_X)/?\`)DOPY_[&'XB?^IOK=`'Z04`%`!0`4`?-WQJ7
M_A%_'OP4^*!Q#I^B>*+WP5XDN.B0:-X]M$TVTN[E]I$=K;:Q!:EFP.;I<D`\
M?<\*OZ_D_%?#ZUK8K"0QV%CU=;+YNK.$%I>=2C*=EVB]#\YXS3RO/>"^)KNG
MA\#C:F7XR6RC0S.G[&G4J/[-.C6C%N7>:3=F;FO1)X/^-.@>)IT"Z!\3=`'P
M]U:1ABWM_%6D3W6K^$GNL_*1J-A<:[IREAS+':1Y_>`'EP<GF7"N,R^F_P#;
M,@Q']HT8KXI82M&%'&*'5>PJ1P]=VV@ZDK>ZVNS'P63<:8#,IQ2R_B7"_P!E
M5VU:,,=0E.O@'/H_K%*>)PT;K6HJ4+^]9X^A:1?Z)';^#;.))?%'PHO+J_\`
M"-K<R+`GB[X9:NTMLFFPW$JB,20V,J:5(Q!2'4-!TV:<K!=(7Z<9B:.)<\SJ
M2<,OXAA"GC)13;P6:T;3=648N]IU$\1%;SPV(KPIWG3DEQX#!U\%&GDU&"EF
MG"=2=7`0FU%8_)<0Y05&,Y)13A2DL)-_#3Q>%PU2K:G5BY>C>%M8BM-/CAT^
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MKVR\J+4[2UNDNO[/NY(A*;6:1%7$@5LX9$8J58J`PK"K0G1Y9<DXTJG,Z4Y0
M</:03MSQ3;T;[-J]U=V9T4,13J\\(SA[>ARQK4X34_8U'%2Y)-):I.^JBVK/
ME2:-"L3H*M]96FI65YIU_;Q7=A?VMQ97MI<()(+JTNHG@N;>:-N'BDAD=&4\
M$,1WH`_-#P%\(OVLOV./[>\$?`CPWX,_:$^`5SK6H:[X'\%^*?&H\`?$7X>#
M5[LWNH^'[77M3LYM)U?11<37$J-,RR/+(\VV!II4E`/M'X+>)OC;XHTG6-0^
M-?PP\.?"G45OX4\/^']"\<0>.[E]--ONN)]9U.RL+6TANQ<_*L=MYJE>2V>H
M&WD>(^!/@]\0=$_;H^.7QIU'188/AQXS^$W@7PMX<UM=5TN6>]UO1/[&_M&U
M?2(;IKZT6/[+<XFGMXXVV#8S;Q0!:_:E_9L\7?$_7?AS\9O@KXLT_P`!_M`?
M!NXOY/!^KZU!-<>&/$^@ZJACUCP7XMBMHWF&E74;3JD\4<IB%]>)LS=":U`_
M`RO#WQ0_;MNM:T;0/$7[+7PRTFS_`+3TZW\0>/;3XY6%WX?32S/;IJNI:/X7
M32#K3SBW^U206EPZG=Y2/*?F:@#Q[Q)X6_:P^%'[7WQX^,OPG_9[TCXN^$/B
MEX9^&NA:?=7WQ:\(>`Y+1_"7A^SMKV7[)JLD]T^Z_-S#MDMX1BW61&=9*`.B
M^,W@[]IK]J/X6_#3X9^.O@[8?"C2/%7QCTR?XYZ?8_$OPWXI33_A#X1N-/UN
M&*VU+39[66_O]?U3;&EO8PS/;'109RD=RK``]&G_`."<W[%<T,\*_`7PS`98
MI8A-!J?BA9H3*C)YL);7F5)4W;E)4@$`X-`'AWP__8Z^(7CC]D'5/V6_C=)/
MX4UGX7_$#4I_@7\3=-U'2=;NTT?1-3GU+P%XOBMM+U+SK.2*/4=5TR73KIK2
MX2PFB5&BE"M`!^!Z)HOCO_@HCX)TZS\*>(?V?/A1\8]3T^)=/3XF^'/C'8^!
MM,UA+=A##K&M^&?$&BM>V][/;IYUPEC&$,TC"**-.%`.,_:1^'7[46N?%K]C
M[X\>!O@_X<\>>+/A#X?\<W/Q!\&V7Q%T/PQHEGXC\8:#I&E2Z;I6O^)7@GO;
M""=]2DBNDL9"ZV,8E2/SQ@#;RL?1/PR\<_M._$!?&FA_&']G'2/@[I;>#]2'
MA_5[#XN^&/'LFL:]<@6<6CR6.CV\+Z=&;>>6;[7*WE@P;#RX(`/B3]EBR_;U
M_9@^"WAWX.6G['GA[QE%X?O_`!#?+X@F_:"^'VA/='7];O=:,;::AO1#Y+7I
MAR+AMXB#84L0`#]=]!NM5O=#T:\UW3$T36[O2M.NM8T6.]BU&/2-5GLX9=0T
MR/4(`(K]+6[>:`7$8"2B(.H`84`:M`!0`4`<QXS\)Z5XY\*Z[X1UJ-GTS7M.
MGL)RG$UNT@#6]Y;M_!=6URL-Q$W\,D"'M7?E>8XC*,PP>981\M?!5(U(I[-+
M24)+^2I!RA-=8R:/,SC*L+G>5X[*<9&^&QU*5*5MX-ZPJ1OHITYJ-2#Z3BF>
M.>"YQX^\*^(/@S\3]Z^.?"5O;Z;K,L4C6=YK&GV\J/X6^)/ANX(#*9I+>UN5
MN(MQM=1M9(Y`I"J_U&:0_L7,<%Q1P_;^R,RE*K0BTIPH5))K%Y9BHK3W5*=-
MPE95L--2BVKM?'Y/-9[E6/X-XFO'.\JA&CB)1;IU,12@T\%F^#GO>4HTZJJ1
MNZ.+@XS47RQ<XN9[BZTCP5\2+Y_#_P`0-'N'/P_^)&GQ1V=GXJ(A\LW6FO,K
MVL.M7%L@BU?PO=EX[C!EMDFMS%):Q[.%*GB<UR*BL7DV)BO[1RRHW.>#]Z_)
M546JCH0F^;!YA3M*GI"JX5.>-2E4G.KA,DXCKO+\_P`'-O*LXI15.GC7RVYZ
M+DG2CB*D%RX_*ZMX5M9THU*7)*ET-S;:Q:7(N?$_A2^N=35$MO\`A-/AQ<R6
M\][!'DQG4]%^W0ZA"`BX^S?\3F%"YV2#<`.*G/"RI^SR_,:=+#W<_J.9P4HT
MY/?V5?V<J+U?\3_99R2]Z+L>A4I8RC5]IF>55*F*24/[1R>;A*I%?"ZV']K#
M$1T5O9_[93BW[LU?2&?4[.YS$\/QBUL%03IJZ)J>@Q,"-AMY+X:?HL;95LL)
MK[:03EJJ&'JTK2C+)<'9_P`3V]*NUUYE3]IBI+RY:-UV)GB:-3W7#B'&Z?P5
MAJV%B[Z<CJ*E@HO?53KV?5FKIL>MZ=%#?:C'H?PP\$:%OO9]*BN=-N+^]CC#
ML\NO:L5&G:+8[RLDJVKW<TS#+WL8+))SUWA*LI4:#KY_FN+M"-5QJQITV[66
M'HW]O6J6O&#J*E""T5"3LX]6&CCL-"%;$1PW"^28&]25",Z,ZM1*[;Q5>WU?
M#TKVE45*56I4>LL3%.49=OX=\0Z=XFTN+6=(^UG3;B29;.XN[&ZT_P"V0Q2-
M&M]:0WD4<DMA/MWP3[`DT;+)&61U8^3C<%7R[$2PN(Y(UZ:BYQA4A4Y)25W3
MFZ;E%5(WM4A>\)7C*TDTO;R[,,/F>%CC,)[3ZM4E)4Y5*4Z/M(Q;2J4XU(QE
M*E.W-3J64:D+3C>+3>Y7(=P4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0!YMX_P#AY'XN.G:WHNIR^%?'GASSI/"_BVSA266U\X`W&DZO:,0FL>&[
MPJHN;"4@'`DB:.50]>[DV=/+/;X3$X=8_)\;98K!S;BIV^&M1FM:&)IW;I5H
MZKX9*4&T?.9]P_'-?J^-P6)EE6>9;S/!XZG%.4.;XJ%>F[*OA*NU6A-V?Q0<
M9JYQ+?$#2+B#_A!OCSX;TWPMJ%ZXLTNM307WPX\52#'E76@>([N(0V-T[8D2
MPU(V=[`[*(S*5$A]59+B:<_[6X.QU7'T:*YW"D_9YG@UUCB,-!\TX+9UJ"J4
M*BOS<B;B>(^(,)*']A\=Y=1RO$5G[-3K+VN48Y])X7&5(J%*;?O1H8ET<33D
MTH<[7.=;:^!-7TA(O^$*^(6N:=I9,;P:3KL=MXUTF&WP"L6GW6I21ZK#`4VJ
MJ_VK+&J\(@R"/-J9OAJ[DLTR6A6Q"NI5L.YX"LY=74A23P\I7NV_JT9-_%)Z
MW]:ED6,P<8_V)Q#B<-A='&AB8PS&A&&ZC2G6<<5&+5E%?6Y04?ABM&K4NC?%
M.YC:$^.?"FF@CY;K3O`EY)=*01P%U'QA<08*YSF(\GBHCB>'J;4EE&+K6^Q4
MS""A]]+!0G_Y,O,TG@^*9Q</[<P.&72='*ZCFOE6S"I3U6_N/R.?U7PAX)\/
M(OBGXJ>,+CQ"-/D%U!=^/=6TZR\-Z?<QC<LNG>&K2&QT=;I<)Y;O:7-R&12D
MF\Y/9A\RS7&-Y=P[E<<#[9<DH9?1JSQ52+W57%3E5Q/(]>9*I3I--\T>7;S\
M5D^29?&.9\4YQ/,%AY<\)YI7HTL'1FM4Z.#IQH8-36G(W2J5DTG&?,[M^D^.
M?%7CW5].;P-HLFD^`[:\AN-4\;>*M/NK.7Q)9Q2!GT[P7X?G,%W)#<J-C:S?
MK;PHC,UM#<M@JL1E&79+AJZS;%+$9Q.$HTL#A*D)K"S:LJF.Q$>>FI0>JPM%
MSG*5E5G25TZPF>9IGV+P[R/!/!Y#2J1G6S''4ITWC*<7=T<NPDO9UG&JM'C*
MZITXQ;=&G6=FO9:^7/L@H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`J7UA8ZE:3V&I65I?V-RABN;*^MH;JTN(V^]'/;7"-'*A[JRD5I1K5L-4
MA6P]6="M3=X3IRE"<7WC*+4HOS31E7P]#$T9X?$T:>(H5%RSIU81G3FGNI0D
MG&2\FFCRY/@GX+T]G;PO+XG\#"0NSV_@WQ7KFB::3(%!VZ(EY)ID.-JD>59I
MTKZ%\5YK52CCXX7-N6UI8W"8>O5T_P"G[A&N]W\55GRT>"<EPSD\KGC<BYKM
MPR['8G#4=;;895)8:.R^&C$:/A+<;E$_Q6^+UQ"NX&W/BC3+16#*5`:XTWP]
M;70P#P5N%.>22>:?^L<$GR<.9-3ETDL)5G;KI&KB9T]?.#71*PEPE4NN?BO/
MYPC?W/KM&FG=6UG1PE*KIW51.^K;9;T;X+_#C1=0AUC_`(1_^W-=MPOE:]XM
MU'4_%VKQ.H0"6"\\1WEX;.7Y%^:V$/3@"LL5Q3GF(HRPJQOU/!RWP^#ITL%1
M:UTE##0I*:U>D^8VP7!?#F"Q$,9_9_UW'4[<N*Q]:MC\1%Z>]&IC*E9TY:+6
MDH'J=?/'U(4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
F`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>c93722p9372202.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c93722p9372202.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`"<"D0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/W\H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@"M>R/#9W<L9VR16T\B$@'#QQ.RG!X.&`X-`'QQI?Q$\8VOA
MGPYXP/C2XU;7-4\7C1;GP9<0:2UM>Z>T[QE[.UM;6.[M)=JH/,#E<S+C'`<`
M^T*`"@#Q3XR^(==T./P79Z)J\VB+X@\4VVD:C>6T=HUREG.F&,,EW#(D#J6W
M[MO\(SE<@@!\/=>\0'QOXT\(7>LS>*M"T"#3YK'Q!<0VBW,%Y=+&TVDW=U80
MQ07,Z^9*3A`R_9FR!NP`-OD>UT`%`'RP_BO5[WXI>+/#NI?$JY\(Z9IVI:;#
MH=F(-)*W\UP;97TV(W=L78LS#HQ;]_P>!0'X'U/0`4`>(?&?Q;K/AE/"=K9:
MG/X<T?6M8>TU_P`36UDE[<:5:1K"R+!'+'(D<DN^5]Q1F(MV"`\@@;>1Z3X0
M_P"1?L7'B9O%T<@EE@UYTLD:[MY)7:)3]@18F:),1%L!B4.X`Y``.FH`SM8N
M;JRTG5+RQMC=WMII][<VEH`2;FY@MI)8+<!2"?,E55P.3NXYH`\,^#'B._\`
M%G_$WU/X@W.I:N8;S^V?!4MCIUG!IDC7.RVEM%6!+D011J,NK.I:?8^&3!`/
MH2@`H`*`"@`H`\`\8ZSK]W\5]-\'0>+;[PKH3^%)M9FGT]=+BD6\AEO1OFN-
M0M)08"L,>Y"0,(<%22:`.I^#OB;7O%'A2:]U]UN9[36=1TVSU9+=;5-9L+1H
MU@U!88P$^9FD0O&H5O*R!G-`;>1ZM0!%.Q2"9E.&6*1E/H50D'\Q0!\R_!?Q
M3JGBB\MY]=^)-Q/JT=YJJ#P9)!I2?;;""WVQ7K&.V2X5$>8R90@9@`.030!]
M/T`%`'BEWXEUV+XYZ5X7CU&5=`G\*3W\VF!(/)>\47FV<OY7FAAY:<!P/EZ4
M`>UT`%`'C?QS\1:WX7\$QZEH&H2Z9??VYIMJ;F%(7?[/.MT98]L\;KAMBG.W
M/R]:`.D^'5Q%=:3=7-OXZD\>1/>[!J+QV$8L9([>$RV"C3XD4D%UD.\%@9<=
M*`V/0*`"@#YDM_B/XB_X6I%-+?'_`(5_?>*+_P`!6=L%@%O_`&Q8Z?;G[8)O
M*\S]YJ,FT'S-I#,`/EH`^FZ`"@#R;XS>)]=\)>#CJ.@,UK-+JEC8WFII;+=O
MI.GW)D^T7R0."AD!5(U9P5#3#H2I`!N_#R6.XT,W5OXWG\=6ES<E[;4[B&Q@
MFM5$42R64JV4,1$BRAG*SHLB^:%(P`2`=Y0`4`?+/@#Q9JVO>,]8LM;^)-SI
MTVG^,;ZRTCPLT&E`:W86MS=N;52UL)_+6.$QEHVW`(3G-`'U-0`4`%`!0`4`
M%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0
M`4`%`!0`4`%`!0`4`%`!0!6O(GFL[N&,`R2VT\2`G`+O$RJ">PR1S0!X_P#"
M'X;IX2\/6I\1:#HT?BF"]OY!J$<5I>W<=O+-NMA'J`CWH1%QA6!4<=S0![30
M`4`>/_%GP7JWC!O!4>FV=K>6ND^*+?4-9ANKB.W0Z6$\NY4+(/WQ:-G7RUY(
M-`#OAIX4\1>!+_Q+X<EAMYO!;7\NJ>%KY+J(W=J+ME:XTVZMMHDPNY=LAR-T
M,AZ2C`&WR/7J`"@#YU@\)>.=#^)'B_Q/8^$]$U_3/$%W8?9)+[6;6TELHK?R
M"]W'#):3,LP(?"C83Y:G/-`'T50`4`<#X^'BF73XK'P[X6T+Q3;7J7<.JV>N
MWRV<,2E(_LCQQR(4N%\PR%U+*PV+L()R`#.^$?@K4?`7@^+1M5N(9K^:^N]2
MN(K9V>ULVN_*`M()&"F0*L09G"J"\CXR.6`V/3Z`*UXUTEG=O81137J6T[6<
M$\AB@ENEB8V\4TB@F*)I@BLP!(!)QQ0!X)X:\#^+[[XEVOC_`,1:'H/A!-/T
MVXM9+'0[X7LNM7ES#/"]U=21(B;<7!+,X#L((5*D@N`-OD?0E`!0`4`%`!0!
MX#XY^%E[XT^()U"\MK8^&;CP5<Z*UXUQ']JL]8,MY-97$-I]]C%++"^\'!&Y
M3P30'X'?_#2S\5Z5X5LM'\7VUM%J6CYTZWN;2YBN(M0TZW`6RN6$04PS"+$;
M*R@GR@YR7.`-O([^@"*92\,J+]YHI%4'CED('/;DT`>`?"'PKXV\$K%HNL>$
M]$6RDU#4[V?Q'%K%K-J-JEU`#%;1VB6I>6-I88T.)U`$S''R\@'T)0`4`>#>
M*O#/CBW^*=EX[\-:'I^M6EIX<.E"WN]9ATIFN)6NQ(=S0RLJHLL9!V$-DCC%
M`'N=LT[V\#W,2P7+0Q-<0))YJ0SLBF6))0!YBI(64/@9`S@9H`FH`\F^,_A+
M6_&?@]-'\/P03WZZSI]Z8[BYCM(Q!;K<"5O-D&-V9$PO?)H`ZKP<==^P3QZ[
MX9TOPO+'<*MO::3J$&H07,7DQ[KJ1H+6!8I3(&7:58X0'-`;>1U]`&=J[:@F
ME:DVDQ)/JBV-U_9T,DB0QO?&%_LJR2O\L:>=LRQZ#-`'S)<_!#Q-'\/=.MK/
M6[^3Q997UMKZZ)+?V2Z!'KCW9ENYX)A9B5;A8I9&$S3L&93QA@``?4-@]V]C
M9O?1);WS6MNUY!&ZR1PW31(;B-)%X=%F+@,."`#WH#;RL6Z`.6\72^(H=)QX
M:T/2_$-U+<)#=Z9JUZMC:RZ>\<HN-LCQ.CR[O*&R0;2K/GM0!PGP?\":QX,M
MO$EYK4=A877B/5O[030]*D:73]&@C\[R[>&0X5FQ.5PNX+'!$NYB#@#8]DH`
M*`/G7P#X2\<>$?$FNO<^$]$OM-U[Q9=:H-:DUFU6^TK3Y[FX_>V]K]D>220P
M2A_+$D9RQ4^M`'T50`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
M4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`8&N>%]!\2"U76].COQ9M*UJ))+B/R3.(Q*1Y$L>=PC
MCZY^[QWH`Y__`(5;X!_Z%RV_\"=0_P#DN@`_X5;X!_Z%RV_\"=0_^2Z`#_A5
MO@'_`*%RV_\``G4/_DN@`_X5;X!_Z%RV_P#`G4/_`)+H`/\`A5O@'_H7+;_P
M)U#_`.2Z`#_A5O@'_H7+;_P)U#_Y+H`/^%6^`?\`H7+;_P`"=0_^2Z`#_A5O
M@'_H7+;_`,"=0_\`DN@`_P"%6^`?^A<MO_`G4/\`Y+H`/^%6^`?^A<MO_`G4
M/_DN@`_X5;X!_P"A<MO_``)U#_Y+H`/^%6^`?^A<MO\`P)U#_P"2Z`#_`(5;
MX!_Z%RV_\"=0_P#DN@`_X5;X!_Z%RV_\"=0_^2Z`#_A5O@'_`*%RV_\``G4/
M_DN@`_X5;X!_Z%RV_P#`G4/_`)+H`/\`A5O@'_H7+;_P)U#_`.2Z`#_A5O@'
M_H7+;_P)U#_Y+H`/^%6^`?\`H7+;_P`"=0_^2Z`#_A5O@'_H7+;_`,"=0_\`
MDN@`_P"%6^`?^A<MO_`G4/\`Y+H`/^%6^`?^A<MO_`G4/_DN@`_X5;X!_P"A
M<MO_``)U#_Y+H`/^%6^`?^A<MO\`P)U#_P"2Z`#_`(5;X!_Z%RV_\"=0_P#D
MN@`_X5;X!_Z%RV_\"=0_^2Z`#_A5O@'_`*%RV_\``G4/_DN@`_X5;X!_Z%RV
M_P#`G4/_`)+H`/\`A5O@'_H7+;_P)U#_`.2Z`#_A5O@'_H7+;_P)U#_Y+H`/
M^%6^`?\`H7+;_P`"=0_^2Z`#_A5O@'_H7+;_`,"=0_\`DN@`_P"%6^`?^A<M
MO_`G4/\`Y+H`/^%6^`?^A<MO_`G4/_DN@`_X5;X!_P"A<MO_``)U#_Y+H`/^
M%6^`?^A<MO\`P)U#_P"2Z`#_`(5;X!_Z%RV_\"=0_P#DN@`_X5;X!_Z%RV_\
M"=0_^2Z`#_A5O@'_`*%RV_\``G4/_DN@`_X5;X!_Z%RV_P#`G4/_`)+H`/\`
MA5O@'_H7+;_P)U#_`.2Z`#_A5O@'_H7+;_P)U#_Y+H`/^%6^`?\`H7+;_P`"
M=0_^2Z`#_A5O@'_H7+;_`,"=0_\`DN@`_P"%6^`?^A<MO_`G4/\`Y+H`/^%6
M^`?^A<MO_`G4/_DN@`_X5;X!_P"A<MO_``)U#_Y+H`/^%6^`?^A<MO\`P)U#
M_P"2Z`#_`(5;X!_Z%RV_\"=0_P#DN@`_X5;X!_Z%RV_\"=0_^2Z`#_A5O@'_
M`*%RV_\``G4/_DN@`_X5;X!_Z%RV_P#`G4/_`)+H`/\`A5O@'_H7+;_P)U#_
M`.2Z`#_A5O@'_H7+;_P)U#_Y+H`/^%6^`?\`H7+;_P`"=0_^2Z`#_A5O@'_H
M7+;_`,"=0_\`DN@`_P"%6^`?^A<MO_`G4/\`Y+H`/^%6^`?^A<MO_`G4/_DN
M@`_X5;X!_P"A<MO_``)U#_Y+H`/^%6^`?^A<MO\`P)U#_P"2Z`#_`(5;X!_Z
M%RV_\"=0_P#DN@`_X5;X!_Z%RV_\"=0_^2Z`#_A5O@'_`*%RV_\``G4/_DN@
M`_X5;X!_Z%RV_P#`G4/_`)+H`/\`A5O@'_H7+;_P)U#_`.2Z`#_A5O@'_H7+
M;_P)U#_Y+H`/^%6^`?\`H7+;_P`"=0_^2Z`#_A5O@'_H7+;_`,"=0_\`DN@`
M_P"%6^`?^A<MO_`G4/\`Y+H`/^%6^`?^A<MO_`G4/_DN@`_X5;X!_P"A<MO_
M``)U#_Y+H`/^%6^`?^A<MO\`P)U#_P"2Z`#_`(5;X!_Z%RV_\"=0_P#DN@`_
MX5;X!_Z%RV_\"=0_^2Z`#_A5O@'_`*%RV_\``G4/_DN@`_X5;X!_Z%RV_P#`
MG4/_`)+H`/\`A5O@'_H7+;_P)U#_`.2Z`#_A5O@'_H7+;_P)U#_Y+H`/^%6^
M`?\`H7+;_P`"=0_^2Z`#_A5O@'_H7+;_`,"=0_\`DN@#L-,TRQT6QM],TRW6
ATL;176WMT:1EC621YG`:5V8YDD=N6/WO2@-O*Q?H`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
